Table 1.
The baseline characteristics of the 16 enrolled patients.
| Characteristic | Value | |
|---|---|---|
| Age (x ± s, year) | 55.8 ± 10.6 | |
| Sex | ||
| Male | 14 (87.5%) | |
| Female | 2 (12.5%) | |
| Weight (x ± s, kg) | 62.3 ± 9.3 | |
| Chronic HBV infection (%) | ||
| Yes | 13 (81.3%) | |
| No | 3 (18.7%) | |
| ECOG PS score (%) | ||
| 0 | 13 (81.3%) | |
| 1 | 3 (18.7%) | |
| Number of tumors (%) | ||
| 1 | 6 (37.5%) | |
| ≥2 | 10 (62.5%) | |
| Tumor size (%) | ||
| <5 cm | 12 (75%) | |
| ≥5 cm | 4 (25%) | |
| Portal vein invasion (%) | ||
| Yes | 2 (12.5%) | |
| No | 14 (87.5%) | |
| AFP [M (P25, P75), ng/ml] | 8.22 (4.85, 26.7) | |
| PIVKA-II [M (P25, P75), mAU/ml] | 82 (27.3, 255.3) | |
| TB (x ± s, μmol/L) | 13.6 ± 6.7 | |
| ALB (x ± s, g/L) | 38.8 ± 14.1 | |
| Child–Pugh grade (%) | ||
| A | 16 (100%) | |
| B/C | 0 (0%) | |
| Hb (x ± s, g/L) | 139.4 ± 30.1 | |
| WBC (x ± s, ×109/L) | 5.0 ± 1.4 | |
| PLT (x ± s, ×109/L) | 116.8 ± 33.1 | |
| Time to recurrence (x ± s, month) | 15.2 ± 14.4 | |
AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; TB, total bilirubin; ALB, albumin; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; HBV, hepatitis B virus; ECOG PS, Eastern Cooperative Oncology Group performance status.